Clinical trial · Interventional
Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma
Outcome of Percutaneous Ethanol Alcohol Injection (PEI) for the Large and Unresectable Hepatocellular Carcinoma.
NCT03138031CI-TRIAL-00038593completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous ethanol alcohol injection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Percutaneous Ethanol Injection (PEI)
- description
- Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of "8" during the procedure. Postprocedure analgesia may be required.
- interventionNames
- Procedure: Percutaneous ethanol alcohol injection
Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- 3 years
- description
- The percentage of HCC patients who are still alive for three years after they started PEI for HCC.
Secondary outcomes (3)
- measure
- Disease free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Review and sign informed consent; * Between 15 and 80 years of age at time of trial enrollment; * Documented pathological and/or radiological diagnosis of hepatocellular carcinoma; * Radiologically documented tumor size of \> 5 centimeters; * Radiologically documented liver cirrhosis. Exclusion Criteria: * American Anesthesia Association (ASA) Class IV or V and/or any * contraindications to general anesthesia; * Uncontrollable ascites; * Deep persistent jaundice; * Hepatic encephalopathy; * Coagulopathy; * Severe thrombocytopenia; * Unable or unwilling to attend follow up visits and examinations; * Other associated surgical procedure;
References
Publications (0)
Data not yet available
No reference posted for this study.